Monitoring of KRAS -mutated ctDNA to discriminate pseudo-progression from true progression during anti-PD-1 treatment of lung adenocarcinoma

• Published in: Oncotarget Vol. 8; no. 23; pp. 38056 - 38060
• Main Authors: Guibert, Nicolas, Mazieres, Julien, Delaunay, Myriam, Casanova, Anne, Farella, Magali, Keller, Laura, Favre, Gilles, Pradines, Anne
• Format: Journal Article
• Language: English
• Published: United States Impact Journals LLC 06.06.2017
• Subjects: Adenocarcinoma - drug therapy; Adenocarcinoma - pathology; Adenocarcinoma of Lung; Antibodies, Monoclonal - pharmacology; Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Humanized; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - pathology; Case Report; Circulating Tumor DNA - genetics; Disease Progression; Humans; Immunotherapy - methods; Lung Neoplasms - drug therapy; Lung Neoplasms - pathology; KRAS mutation; anti-PD-1; immunotherapy; circulating tumor DNA; non-small-cell lung cancer

Pseudo-progression is a rare but worrying situation for both clinicians and patients during immunotherapy. Dedicated ir-RECIST criteria have been established to improve this situation. However, this can be sometimes considered inadequate and patients experiencing true progression may then receive in...